RT Journal Article SR Electronic T1 12 Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction JF Heart JO Heart FD BMJ Publishing Group Ltd and British Cardiovascular Society SP A9 OP A9 DO 10.1136/heartjnl-2016-309668.12 VO 102 IS Suppl 3 A1 P Kanagala A1 ASH Cheng A1 J McAdam A1 AM Marsh A1 IB Squire A1 LL Ng A1 GP McCann YR 2016 UL http://heart.bmj.com/content/102/Suppl_3/A9.abstract AB Purpose Heart failure with preserved ejection fraction (HFpEF) is a poorly characterised condition. We aimed to phenotype patients with HFpEF using multiparametric stress cardiovascular magnetic resonance imaging (CMR) and assess the relationship to clinical outcomes.Methods and Results Patients were recruited as part of an observational, single-centre, cohort study. Inclusion criteria were: clinical or radiographic evidence of heart failure (HF) and ejection fraction > 50% on transthoracic echocardiography (TTE). Exclusion criteria were: myocardial infarction (MI) in the preceding 6 months, suspected or confirmed cardiomyopathy/ constrictive pericarditis, non-cardiovascular life expectancy < 6 months and severe valve/ lung/ renal disease.Patients labelled as HFpEF (n = 154, 51% male, mean age 72.4 ± 10 years) underwent TTE and CMR during a single study visit. The CMR protocol comprised cine, stress/rest perfusion and late gadolinium enhancement imaging on a 3-Tesla scanner. Follow-up outcome data (death or HF hospitalisation) was captured after a minimum of 6 months.CMR detected previously undiagnosed pathology in 42 patients (27%), who had similar baseline characteristics to those without a new diagnosis (see Table 1). These diagnoses consisted of: coronary artery disease (n = 20, including 14 with ‘silent’ MI), microvascular dysfunction (n = 11), probable or definite hypertrophic cardiomyopathy (n = 10) and constrictive pericarditis (n = 5). Four patients had dual pathology. During follow-up (median = 623 days), those patients with a new CMR diagnosis were at higher risk (see Figure 1) of adverse outcome for the composite end-point (hazard ratio log rank test: p = 0.047). In multivariate analysis, the ‘new CMR diagnoses’ group remained an independent predictor of outcome (hazard ratio: 1.92; 95% CI: 1.07 to 3.45; p = 0.03).Abstract 12 Figure 1 Kaplan-Meier survival plots for the composite end-point of death and/or re-hospitalisation from heart failure stratified according to new CMR diagnosis versus no new diagnosisConclusion Stress CMR diagnosed new significant pathology in 27% of patients with HFpEF and these patients were at increased risk of death and HF hospitalisation.Conflicts of interest On behalf of all authors, there are no conflicts of interest to declare.View this table:Abstract 12 Table 1 Baseline characteristics of the study cohort who underwent CMR